Elsamany, S.A. et al. 2025. Neoadjuvant Chemotherapy Plus Denosumab Compared to Chemotherapy Alone in Hormonal Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Premenopausal Breast Cancer Patients. World Journal of Oncology. (Aug. 2025). DOI:https://doi.org/10.14740/wjon2546.